Buss, Mary K

Beth Israel Deaconess Medical Center

1 paper on CoChatORCID 0000-0002-0410-9463

Most cited papers

Verified
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 263

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free